Pharming Group excels with RUCONEST and JOENJA, showing strong revenue growth and positive cash flow. Check out my recommendation for PHAR stock.

Leiden, the Netherlands Saturday, March 22, 2025, 12:00 Hrs [IST] ...

Hereditary angioedema is a rare genetic disorder characterized by recurring episodes of severe swelling in various parts of ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Zandy Forbes’ biotech company MeiraGTx has developed targeted gene therapy methods to treat more than just genetic disorders. Now it’s on the cusp of its first regulatory approval. Each year ...

Gene Hackman had only been spotted on a few rare appearances throughout the remainder of his life. The Royal Tenenbaums star hung up his hat on his iconic film career at the age of 74, and he died ...

The latest price target for Pharming (NASDAQ:PHAR) was reported by HC Wainwright & Co. on March 21, 2025. The analyst firm set a price target for $37.00 expecting PHAR to rise to within 12 months ...

Across the recent three months, 4 analysts have shared their insights on Pharming (NASDAQ:PHAR), expressing a variety of opinions spanning from bullish to bearish. The table below summarizes their ...

Revenue: US$297.2m (up 21% from FY 2023). Net loss: US$11.0m (loss widened by 4.5% from FY 2023). US$0.016 loss per share (in line with FY 2023). Revenue was in line with analyst estimates ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

ADHD likely has a genetic component. If a biological parent or sibling has ADHD, you’re more likely to have it, too, but this doesn’t mean you will. Your environment can be influential as well.